D.A. Wallach Explains Why Biotech VC Is So Different
December 12, 2025 at 9:00 AM UTC
Listen to Odd Lots on Apple Podcasts (https://podcasts.apple.com/us/podcast/odd-lots/id1056200096)
Listen to Odd Lots on Spotify (https://open.spotify.com/show/1te7oSFyRVekxMBJUSethH?si=66d0fe8845e4474a)
Watch Odd Lots on YouTube (https://www.youtube.com/playlist?list=PLe4PRejZgr0OJbRzA6nWybYiThLJd_ouz)
Subscribe to the newsletter (https://www.bloomberg.com/account/newsletters/oddlots)
Most people picture venture capital as backing software startups or, more recently, funding a hot new AI tool. Yet venture funding also drives the discovery and development of groundbreaking medicines and therapies. That’s the world D.A. Wallach operates in—though his path wasn’t always biotech. Before he became a biotech investor, Wallach fronted the indie rock band Chester French as its lead singer. So, how did he transition from music to venture capital? How does he identify biotech opportunities with real potential? What exactly does it take to bring a brand-new drug to patients? And in what ways does biotech investing differ from traditional VC?
We sit down with the co-founder of Time BioVentures to unpack all of these questions—plus we weigh in on AI’s influence on the music industry and, as a special treat, offer a performance.
